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Abstract
Background The implantable cardioverter defibrillator (ICD)
is effective in preventing sudden cardiac death. However, in
elderly patients (aged 75 years or older) the role of ICDs is still
not well-defined and controversial.
Methods We retrospectively analysed all clinical and survival
data of all ICD patients who were ≥75 years at the date of
implantation in the Erasmus MC, Rotterdam, the Netherlands
and the University Hospital, Basel, Switzerland. Kaplan-
Meier survival analysis was performed, and mortality predic-
tors were identified. Mortality of the cohort was compared
with a random sample of patients aged 60–70 years originat-
ing from the same database and to an age- and sex-matched
cohort of Dutch persons.
Results The study cohort consisted of 179 patients aged
75 years or older who were implanted between February
1999 and July 2008. The median follow-up time was 2.0
(IQR 2.8) years. Survival rates after 1, 2 and 3 years were
87, 82, 75 %, respectively. Survival was similar for primary
and secondary prevention. Mortality in this study population
could be predicted by combining four clinical risk factors:
QRS duration >120 ms, NYHA class > II, renal failure and
atrial fibrillation (AF). Survival was worse compared with the
group of ICD patients aged 60–70 years and to the age- and
sex-matched group of elderly persons. However, survival was
not significantly worse when comparing elderly ICD patients
without additional risk factors to the general population.
Conclusions Elderly patients still have an acceptable survival
probability independent of prevention indication, certainly if
there are no additional clinical risk factors. The presence or
absence of additional clinical risk factors should be taken into
account when making the decision for implantation, since
they strongly correlate with survival.
Keywords Implantable cardioverter defibrillator . Survival .
Age . Comorbidity . Geriatric cardiology
Introduction
Both in primary prevention and secondary prevention trials,
there has been solid evidence that the implantable cardioverter
defibrillator (ICD) reduces the rate of sudden cardiac death as
well as the rate of total death [1–6]. Subanalysis of these large
trials focusing on elderly patients showed that patients
≥75 years also profit from this therapy [7, 8]. However, due
to budgetary restrictions in various countries, it is sometimes
impossible to implant all ICD-eligible patients [9].
A risk stratification system was developed by Goldenberg
et al. based on the MADIT 2 study [10]. The assessment of
benefit of an ICD was based on a simple clinical score system
including age, renal function, atrial fibrillation (AF), New
York Heart Association (NYHA) class and QRS duration.
Maximum benefit from an ICD was seen in patients with 1
or 2 risk factors, while no additional effect on mortality was
seen in patients who had none or ≥3 risk factors. Furthermore,
patients with severe renal failure as the only risk factor showed
no benefit. We published similar observations in a group with
heart failure treated with ICDs combined with cardiac
resynchronisation therapy (CRT) [11].
In this retrospective study, we wanted to assess the survival
of patients with ICDs (with or without CRT) who are 75 years
or older and to study the impact of several risk factors on
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survival, using the MADIT 2 risk score as proposed by
Goldenberg et al. as starting point.
Methods
Patient characteristics
A total of 179 consecutive patients over the age of 75 years
and living in the region of Rotterdam, the Netherlands and the
region of Basel, Switzerland, who received an ICD implanta-
tion, were included in this study. All ICDs were implanted
between February 1999 and July 2008. They were followed
up every 3 months at the ICD outpatient department and all
data were carefully collected in the database each time. Clin-
ical characteristics of the patients were analysed, and correlat-
ed with survival and with appropriate therapy. Mortality of the
cohort was then compared with a random sample of patients
aged 60–70 years originating from the same database, and
with an age- and sex-matched cohort of the Dutch population
obtained from the Dutch Institute of Statistics (www.cbs.nl)
[12]. On this website survival data are given separately for
men and women of every age. We constructed the survival
curve for an age- and sex-matched cohort from these data,
which is comparable with our study group.
Mortality was also determined using the modified risk
factor model proposed by Goldenberg et al. (MADIT 2 risk
score). The modification was necessary as obviously one of
the risk factors, age ≥75 years, was an inclusion criterion on
this study.
Comorbidity
Comorbidity present before ICD implantation was identified
through detailed analysis of the patient chart and laboratory
data. Renal function was assessed by estimating the baseline
glomerular filtration rate (eGFR) using the abbreviated Mod-
ification of Diet in Renal Disease (MDRD) Study equation:
eGFR (mL/min/1.73 m2 of body surface area) = 186 × (serum
creatinine in mg/dL)−1.154 × (age)−0.203 × 0.742 in female
subjects. Impaired renal function was defined as an eGFR
<60 mL/min/1.73 m2. Atrial fibrillation (AF) was considered
to be present if there was at least one documented episode.
Other reported comorbidity included cerebrovascular disease,
chronic obstructive pulmonary disease, diabetes, peripheral
vascular disease, renal failure, body mass index (BMI), and
any malignancy (excluding metastatic cancer).
Statistical analysis
Summary values are given as median and interquartile range
(IQR). Categorical data are summarised as frequency and
were compared using chi-square tests. Survival curves were
composed using Kaplan-Meier analysis, and were compared
by use of the log-rank test. Patients who were lost to follow-up
were censored in the analysis from the time point of the last
visit. The median survival was defined as the time point where
the probability of survival is 0.50. A p-value of<0.05 was
considered statistically significant. The Cox proportional Haz-
ard method was used to calculate hazard ratios of survival.
Results
Patient characteristics
Patient characteristics are summarised in Table 1.
Risk factors for mortality
The median follow-up time was 2.0 (IQR 2.8) years. In
total, 32 % of the patients died during follow-up after a
mean of 74 months, 12 % of the patients were trans-
ferred to another hospital and lost for follow-up, and
56 % of the patients are still being actively followed.
Survival after 1 year was 87 %, after 2 years 82 %, and
75 % after 3 years, respectively (Fig. 1a). Median sur-
vival was 4.2 years (IQR 2.4) years.
Risk stratification according to the four pre-mentioned
risk factors (renal function, QRS duration, NYHA class >
II, AF) showed a good survival in patients with 0 or 1
additional risk factors (except for age): 1-year survival
was 93 and 88 %, respectively, 2-year survival 93 and
84 %, respectively. On the other hand, patients with ≥2
additional risk factors had a 1-year survival of 83 % and a
2-year survival of 76 % (p=0.02) (Fig. 1b). Median surviv-
al was 6.2 (IQR 5.9) years in the patients with no additional
risk factors (except of age), 4.2 (IQR 6.5) years in patients
with one additional risk factor and 3.5 (IQR 3.2) years in
patients with ≥2 additional risk factors. In the group of
patients with no additional risk factors, 23 % died during
follow-up, while this was 30 and 36 % for patients with 1
and 2 or more additional risk factors, respectively.
Age at the day of implantation, the reason for implantation
(primary versus secondary prevention) ejection fraction, dia-
betes, body mass index, a history of myocardial infarction, the
number of leads (VVI, DDD, CRT-D), the presence of periph-
eral vascular disease and pulmonary disease were not associ-
ated with an increased mortality. Only the need for diuretics
was associated with a worse outcome.
Mode of death was cardiac in 42 %, with the majority of
these due to heart failure (62 %). Non-cardiac death was
recorded in 18 % while in 40 % the cause of death was not
specified in the database.
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Risk factors for ICD therapy
Of the patients, 41 % received an appropriate intervention of
their device: 19 % of the primary prevention patients versus
50 % of the patients with secondary prevention indication
(Fig. 2a and b). There was no difference in the proportion of
patients receiving ICD therapies according to the MADIT 2
risk score: patients without risk factors (except for age) had a
50 % chance of an appropriate ICD therapy, those with 1 risk
factor 42 % and those with ≥2 risk factors 36 % respectively
(p=0.39).
Clinical variables as age, NYHA class, AF, renal failure,
medication use, history of myocardial infarction, and BMI
were not associated with the chance of receiving an appropri-
ate ICD therapy. Remarkably, the probability of receiving
therapy was lower in our diabetic population (p=0.03).
The median time to the first intervention was 101 (IQR
270) days. Mortality was higher among patients who experi-
enced ICD therapy compared with those who did not (51 %
vs. 30 %, p=0.05) (Fig. 3a). The 1-, 2- and 3-year survival
after an appropriate therapy was 84, 78 and 61 %. Median
survival was 4.4 (IQR 5.9) years after an appropriate therapy
(Fig. 3b). In every group of patients (according to their addi-
tional risk factors) the risk of dying was higher when appro-
priate therapy was needed.
Forty-nine percent of the patients who died, died without
any ICD intervention (28 out of 57 patients). In patients with 0
or 1 additional clinical risk factors, 29 % died without any
intervention (7 out of 24) versus 64 % in the group of patients
with ≥2 additional clinical risk factors (21 out of 33) (p=0.01).
Comparison of survival
The distribution of ventricular (VVI), atrioventricular (DDD)
and biventricular ICDs in the younger population was com-
parable with the group of elderly patients (not significant).
Survival was significantly better in the control group of
ICD patients aged 60–70 years compared with the study group
(p=0.02). In the younger group of patients, 1-, 2- and 3-year
survival was 93, 83 and 75 %, respectively, versus 87, 82 and
75%. The survival curves only start to separate after 3 years of
follow-up (Fig. 4). The median survival rate cannot be calcu-
lated since the time point that the probability of survival is
0.50 was not reached.
Survival was significantly better in a sex- and age-matched
group of the general (elderly) population of inhabitants of the
Netherlands. Survival after 1, 2 and 3 years in this sex- and
age-matched group is 94, 88 and 81 %, respectively, as com-
pared with 87, 82 and 75 % in the study population (Fig. 5a).
In the group of patients with no additional clinical risk factors
(MADIT 2 risk score 1,–age), there was no statistical differ-
ence in survival between the general elderly Dutch population
and our patients (p=0.65). Survival in the latter group was 93,
Table 1 Patient characteristics
Age (years) 77 (IQR 3)
Male/female (%) 86/14
Device
Single chamber device 40 %
Dual chamber device 35 %
Cardiac resynchronisation therapy 25 %
Indication
Primary prevention 30 %
- Low ejection fraction (<35 %) 64 %
- Low ejection fraction (<35 %) + nsVT 36 %
Secondary prevention
- Ventricular fibrillation 25 %
- Monomorphic VT 66 %
- Syncope suspected to be caused by VT 9 %
Ejection fraction 31±9 %
<25 % 20 %
25–35 % 58 %
35–50 % 18 %
>50 % 4 %
Aetiology
Ischaemic heart disease 82 %
Dilated cardiomyopathy 16 %
Miscellaneous 2 %
- Idiopathic ventricular fibrillation 2 patients
- Hypertrophic cardiomyopathy 1 patient
Functional class
NYHA I 11 %
NYHA II 67 %
NYHA III 22 %
NYHA IV 0 %
Co-morbidity
Moderate to severe renal failure 49 %
Diabetes 20 %
Atrial fibrillation 27 %
Peripheral arterial disease or stroke 24 %
COPD 13 %
History of malignancy 10 %
MADIT 2 classification
0 points 0
1 point (age) 17 %
2 points 37 %
≥3 points 46 %
Medication use
Beta-blockers 68 %
ACE-inhibitors/angiotensin II receptor blockers 71 %
Diuretics 75 %
Statins 66 %
Amiodarone 35 %
Digoxin 12 %
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93 and 88 % after 1, 2 and 3 years of follow-up (Fig. 5b).
Compared with the general population the hazard ratio for
death was 1.2 [0.5–2.7] for the patients with no additional risk
factor (p=0.66); 2.0 [1.2–3.4] for 1 additional risk factor and
3.6 [2.2–5.6] with ≥2 additional risk factors, except age.
Discussion
The main findings of this study are that survival in elderly
patients who need an ICD is good, certainly in those without
additional risk factors. When no additional clinical risk factors
were present, survival was even comparable with the general
elderly population in the Netherlands. Survival was, as ex-
pected, worse in the elderly comparedwith a group of younger
ICD patients, but the curves only started to diverge after
3 years of follow-up.
Risk stratification
Risk stratification is an important tool, which can guide us to
predict which patients have most benefit from the implanta-
tion of an ICD. Different strategies have been proposed such
as T-wave alternans [13, 14], signal-averaged electrocardiog-
raphy [15, 16], invasive electrophysiological study [17] and
heart rate variability [16]. The risk stratification first described
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by Goldenberg et al. is simple and based on clinical risk
factors [10]. Applied to the primary preventionMADIT 2 trial
it proved to be an effective tool to help in distinguishing those
who will benefit from an ICD from those who are too well or
too sick to gain benefit from an ICD. When translating this
risk scheme to our mixed primary and secondary prevention
group of elderly patients, it proved to be a good predictor of
mortality as well. Some of these risk factors (QRS duration,
age, renal function) were also seen in a recent paper looking at
outcome in a cohort of Dutch ICD patients [18].
Due to the increasing age of the population in Europe,
the group of elderly patients with primary and secondary
prevention indications will increase in number. Our data
implicate that age in itself should not solely be a reason
for exclusion from ICD implantation. Patients without
any additional risk factors except age (MADIT 2 risk
score: 1) had a survival comparable with the general
elderly population. At first sight this may seem contra-
dictory since we studied a group of patients with severe
cardiac disease. However, when assessing the survival
curve of a general age-matched elderly population, this
survival curve includes not only healthy elderly people
but also persons with different pathology (e.g. cancer).
Furthermore, the survival curves between the younger
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ICD patients (60–70 years) and our elderly group of patients
only started to diverge after 3 years of follow-up.
Implanting an ICD in a patient is not only based on scien-
tific data but also on budgetary reasons in some countries,
mostly in agreement with the guidelines [19]. Simple risk
stratification with easily obtained clinical factors such as renal
function, QRS duration, NYHA class and AF, can be a guid-
ance in the process of decision-making, certainly in the elderly.
We do not say that ICDs are not useful in elderly persons
with ≥2 additional clinical risk factors since this is a retro-
spective study not randomising patients. Survival after ICD
and benefit from ICD are separate issues. However, patients
with ≥2 additional clinical risk factors die sooner and with a
higher chance of not receiving appropriate therapy, compared
with those with 0 or 1 additional risk factor.
Comparison with other studies
In a sub-analysis of the MADIT 2 trial, it was found that
implanting an ICD in patients ≥75 years was associated with
a similar risk reduction in total mortality compared with
younger patients (44 % versus 37 %), implicating that age in
itself might not be an exclusion criterion for ICDs [7]. Also,
Koplan et al. found that in octogenarians with an ICD the
median survival is 4.2 years, whichmatches well with our data
[8].
The implantation of a transvenous ICD is no longer a major
procedure and not associated with a long convalescence. The
risks associated with implantation are minor and there is no
decrease in quality of life after an ICD implantation [20].
This study only addresses mortality and not quality of life
or cost-benefit. These factors are of equal importance in an
elderly group of patients. According to recent studies costs
remained under 100,000 $ per quality adjusted life year gained
when the expected survival was ≥7 years [9, 21]. Median
survival in our group is estimated at around 4.2 years impli-
cating that the cost per quality adjusted life year gained is
higher. However, when we only assessed patients with no
additional clinical risk factors except age the median survival
became 6.2 years. Furthermore, in recent years costs of ICDs
have decreased in Europe which will probably lead to a lower
cost per quality adjusted life year [9].
Limitations
This study is descriptive and retrospective in nature and is not a
randomisation of elderly patients to ICD implantation or opti-
mal medical therapy. It only gives us an idea about survival in
elderly patients in whom an ICDwas already implanted. There-
fore we do not have a control group of elderly non-ICD patients
with similar characteristics. A selection bias is evident. All
patients with the same risk profile as discussed in this study
received an ICD. If an elderly ICD candidate did not receive the
device this was probably due to a too high burden of comor-
bidity based on our clinical judgment. This may explain why
the survival curves are similar between our younger and elderly
ICD patients during the first 3 years. On the other hand, in
younger patients selection bias will probably play a minor role
compared with the elderly. Therefore, this study cannot be
extrapolated to an unselected group of elderly patients needing
an ICD for primary or secondary reasons.
The differences in the follow-up time between the primary
and secondary prevention indications are due to the fact that
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we only started to implant for primary prevention reasons after
the publication of MADIT 2 [1].
Conclusions
Elderly patients, as selected in our hospitals, still have an accept-
able survival, independent of prevention indication and therefore
can still benefit from ICD therapy. It would be improper to
withhold ICD therapy only based on age criteria, certainly if
there are no additional clinical risk factors. The presence or
absence of additional clinical risk factors should be taken into
account when making the decision for implantation.
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